Rep. Kevin Hern Sells Off Shares of Medtronic PLC (NYSE:MDT)

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Medtronic PLC (NYSE:MDT). In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $15,001 and $50,000 in Medtronic stock on March 20th. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Exact Sciences (NASDAQ:EXAS) on 3/24/2026.
• Sold $50,001 – $100,000 in shares of Prologis (NYSE:PLD) on 3/20/2026.
• Sold $15,001 – $50,000 in shares of T. Rowe Price Group (NASDAQ:TROW) on 3/20/2026.
• Sold $500,001 – $1,000,000 in shares of Smartstop Self Storage REIT (NYSE:SMA) on 3/18/2026.
• Sold $500,001 – $1,000,000 in shares of Texas Instruments (NASDAQ:TXN) on 3/18/2026.
• Sold $50,001 – $100,000 in shares of BlackRock MuniAssets Fund (NYSE:MUA) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Cognizant Technology Solutions (NASDAQ:CTSH) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Invesco (NYSE:IVZ) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Becton, Dickinson and Company (NYSE:BDX) on 3/17/2026.
• Sold $15,001 – $50,000 in shares of Comcast (NASDAQ:CMCSA) on 3/17/2026.

Medtronic Stock Performance

Shares of MDT stock opened at $86.27 on Tuesday. The business’s fifty day simple moving average is $94.18 and its 200-day simple moving average is $96.19. The company has a market cap of $110.77 billion, a PE ratio of 24.03, a PEG ratio of 2.24 and a beta of 0.75. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be given a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.3%. Medtronic’s dividend payout ratio is presently 79.11%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on MDT shares. Citigroup started coverage on Medtronic in a research report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price target on the stock. Sanford C. Bernstein boosted their price objective on shares of Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a report on Friday, January 9th. JPMorgan Chase & Co. dropped their price objective on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. Daiwa Securities Group dropped their price objective on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Finally, Argus dropped their price objective on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $109.85.

Institutional Investors Weigh In On Medtronic

Hedge funds have recently added to or reduced their stakes in the business. Monetary Solutions Ltd purchased a new stake in Medtronic in the fourth quarter valued at $27,000. Corundum Trust Company INC purchased a new stake in Medtronic in the third quarter valued at $27,000. Lodestone Wealth Management LLC acquired a new position in shares of Medtronic in the fourth quarter worth about $27,000. Anfield Capital Management LLC raised its position in shares of Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the period. Finally, Board of the Pension Protection Fund acquired a new position in shares of Medtronic in the fourth quarter worth about $29,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.26% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).